fashion -WSS

fashion

author：entertainment 2025-10-02 23:59:47 - browse：5

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — The booming obesity market is attracting another player, as pharma giant Roche said Monday it was acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates for $2.7 billion upfront.

The deal for Carmot, which is based in Berkeley, Calif., includes additional milestone payments of up to $400 million. Carmot is privately held, though it had filed paperwork last month for an initial public offering.

As part of the deal, Roche is gaining three experimental obesity medicines from Carmot, which are in Phase 1 or Phase 2 testing, as well as preclinical programs. While two are injectable treatments, one is being developed as an oral drug. They all target GLP-1 hormone receptors, while two are also designed to work via receptors for another hormone called GIP.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Rep. Raul Ruiz on the physician shortage and more

focus

WSS

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

J&J to emphasize cancer drugs, stop much of its vaccine research

UnitedHealth’s Optum accused of antitrust violations in California

What to do when lifesaving products contribute to climate change

Boston's new lab space is opening empty

UnitedHealth’s Optum accused of antitrust violations in California

focus

fashion

focus

Alkermes shareholders re

FDA advisers back CAR

State Dept. review finds Biden bears some blame for Afghanistan failures

Why scientists need input from humanists on sensitive research

Supreme Court strikes down use of affirmative action

CDC director unscathed in first congressional testimony

Jerome Adams on the need for new antivirals for Covid

Why depression after traumatic brain injury is distinct

BioMarin wins approval for gene therapy to treat hemophilia A

Mayo Clinic plans $5B tech

Wikipedia

Will the market for weight loss drugs really reach $100 billion?

FDA investigates CAR

Readout Newsletter: CAR

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

What don’t we know about an Alzheimer’s drug side effect?

Flagship Pioneering launches a new biotech in two countries

entertainment

focus

entertainment

focus